Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy | NeoGenomics Laboratories

Publication date

Thu, 09/16/2021 - 12:00

Category

Year

Subtitle

ESMO 2021

File

Clinical_utility_of_ctDNA_for%20detection_ESMO_2021.pdf (874.62 KB)

Division